cutamesine
Small moleculeexperimental
Cutamesine (SA 4503) is a synthetic sigma receptor agonist which is selective for the σ1 receptor, a chaperone protein mainly found in the endoplasmic reticulum of cells in the central nervous system. These σ1 receptors play a key role in the modulation of Ca2+ release and apoptosis. Cutamesine's activation of the σ1 receptor is tied to a variety of physiological phenomena in the CNS, including activation of dopamine-releasing neurons and repression of the MAPK/ERK pathway. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00551109)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Delta opioid receptorINHIBITOR
OPRD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCutamesine ↗
Also known as
- (11c)sa4503
- 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride
- cutamesine
- sa4503
- sa4503
- sa4503
- sa 4503
- sa-4503
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00639249 | Phase 2 | Feb 1, 2008 | M's Science Corporation, University of Glasgow |
| NCT00551109 | Phase 2 | Nov 1, 2007 | M's Science Corporation, University of Helsinki |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| M's Science Corporation | For profit | 2 | 2 | 1 | 2007 |
| University of Glasgow | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Helsinki | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1